Non-Cystic Fibrosis Bronchiectasis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment (Surgery, Physiotherapy, Vaccination, Airway Pharmacotherapy, Antibiotics, Others), By Diagnosis (CT scan, Bronchoscopy, Chest X-ray, Lung function, Sputum culture test, Blood tests, Others), By End use (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition, 2020-2030F

Market Overview

The Global Non-Cystic Fibrosis Bronchiectasis Market, valued at USD 3.71 Billion in 2024, is projected to experience a CAGR of 5.30% to reach USD 5.06 Billion by 2030. The Global Non-Cystic Fibrosis Bronchiectasis (NCFB) market addresses a chronic lung condition characterized by the permanent dilation and thickening of the airways, distinct from cystic fibrosis, which leads to impaired mucus clearance and recurrent respiratory infections. The market is primarily driven by the increasing global prevalence of chronic respiratory diseases, alongside significant advancements in diagnostic technologies, such as high-resolution CT scans, facilitating earlier and more accurate disease identification. According to the Global Initiative for Chronic Obstructive Lung Disease, a founding member of the Forum of International Respiratory Societies, in 2024, bronchiectasis was estimated to affect one million individuals worldwide, with approximately 400,000 cases in the United States.

Further market expansion is supported by growing awareness among healthcare professionals and innovations in various treatment modalities, including novel antibiotics, mucolytics, and airway clearance therapies, which collectively enhance patient management. However, a significant challenge impeding market growth remains the limited availability of specific, disease-modifying therapies for NCFB, with many existing treatments utilized off-label or focusing on symptom management rather than underlying disease progression.

Key Market Drivers

The increasing global prevalence of non-cystic fibrosis bronchiectasis (NCFB) stands as a primary market driver, directly raising demand for diagnostic and therapeutic resources. This trend is fueled by advancements in diagnostic technologies, heightened clinician awareness, and a deeper understanding of NCFB’s diverse etiologies. NCFB’s chronic and progressive nature, often involving recurrent infections, necessitates continuous medical management. As diagnostic methods become more precise, leading to earlier identification, recorded prevalence rates steadily increase. For example, according to an article published in *Lancet Respiratory Medicine*, in July 2023, the European Bronchiectasis Registry (EMBARC) documented 16,963 individuals enrolled between January 2015 and April 2022, highlighting a significant and growing patient cohort within Europe. This expanding patient base directly fuels the need for effective solutions.

The development of novel therapeutic modalities profoundly influences the Global Non-Cystic Fibrosis Bronchiectasis Market. Historically, NCFB treatments were primarily repurposed for symptom management. Recent research and development efforts now yield disease-specific therapies targeting underlying pathophysiological mechanisms, aiming to reduce exacerbations and improve patient quality of life. A pivotal regulatory milestone demonstrates this progress: according to an Insmed press release, on August 12, 2025, the U. S. Food and Drug Administration approved brensocatib (Brinsupri), establishing it as the first and only FDA-approved treatment specifically for non-cystic fibrosis bronchiectasis. Such dedicated treatments offer new care pathways and incentivize further market investment. This specialized nature of NCFB care is further highlighted by healthcare patterns, where according to a presentation at the CHEST Annual Meeting, in October 2024, a study found 39.1% of patients sought care from a pulmonologist, underscoring reliance on specialist expertise.

Download Free Sample Report

Key Market Challenges

The limited availability of specific, disease-modifying therapies for Non-Cystic Fibrosis Bronchiectasis significantly constrains market expansion. Current treatment approaches predominantly focus on managing symptoms and complications, such as recurrent infections, rather than addressing the underlying disease progression. This reliance on symptomatic or off-label treatments creates a substantial unmet medical need and restricts the development of a dedicated market segment for truly transformative interventions. Pharmaceutical companies face reduced incentives for significant investment in a therapeutic area where targets for disease modification are not well-defined or approved pathways are limited.

Consequently, market growth is hampered by a lack of novel, high-value products that could fundamentally alter the disease course. According to data presented at the 2024 European Respiratory Society Congress from the EMBARC registry, a notable patient population continues to experience frequent disease episodes under current treatment regimens. Specifically, 20.5% of patients had three or more exacerbations in the year of study inclusion, with an additional 25.5% experiencing two exacerbations. This consistent recurrence of acute events underscores the inadequacy of existing therapies in providing sustained disease control and highlights the urgent need for treatments that can modify disease progression, thereby limiting the overall market potential for the condition.

Key Market Trends

The development of disease-modifying and biologic therapies signifies a pivotal evolution in the Global Non-Cystic Fibrosis Bronchiectasis Market, shifting beyond symptomatic management to interventions that directly alter disease progression. This focus includes advanced biologic agents and small molecules designed to reduce inflammation or disrupt bacterial colonization. According to the American Thoracic Society (ATS) 2025 International Conference, in May 2025, the average initial hospitalization for NCFBE patients was 7.1 days, costing 22,355 USD, highlighting the substantial burden new treatments aim to alleviate. Armata Pharmaceuticals, in July 2024, announced full enrollment in its Phase II Tailwind study of inhaled AP-PA02, targeting *Pseudomonas aeruginosa* infections in NCFB patients, signaling progress in anti-infective strategies with potential disease-modifying effects. This trend promises more profound and sustained clinical benefits.

The integration of digital health and artificial intelligence solutions is fundamentally reshaping the Non-Cystic Fibrosis Bronchiectasis Market by enhancing diagnostic precision and optimizing patient monitoring. These technological advancements enable remote assessment, real-time data analysis, and predictive modeling, improving care efficiency and accessibility, vital for NCFB's continuous management. AstraZeneca, in February 2024, highlighted its collaboration with ArtiQ to explore artificial intelligence in home spirometry, demonstrating how digital tools can facilitate earlier diagnosis and more consistent disease monitoring for respiratory conditions, including NCFB. Such solutions empower patients with greater self-management, providing healthcare providers crucial data for proactive intervention, potentially reducing exacerbation rates and improving quality of life.

Segmental Insights

In the Global Non-Cystic Fibrosis Bronchiectasis Market, the Surgery segment is experiencing rapid growth due to its critical role in managing severe disease presentations. Surgical interventions, such as lung resection, become essential when specific lung sections are severely damaged and unresponsive to conventional medical therapies, thereby enabling the remaining healthy tissue to function more efficiently. Furthermore, surgical procedures, including the use of endobronchial valves, are vital for restoring lung function and addressing issues like bronchial strictures or blockages that impede breathing. These targeted approaches aim to improve patient outcomes and quality of life, cementing surgery's position as a fast-growing segment in the treatment landscape for non-cystic fibrosis bronchiectasis.

Regional Insights

North America holds a leading position in the global Non-Cystic Fibrosis Bronchiectasis market, primarily attributed to its advanced healthcare infrastructure and substantial healthcare expenditure. The region benefits from a high disease prevalence alongside increased awareness, leading to earlier and more accurate diagnoses. Furthermore, a robust regulatory framework and well-established reimbursement systems support market expansion by ensuring patient access to treatments and promoting effective respiratory disease management. The strong presence of key market players and continuous advancements in research and development, including innovative therapies and diagnostic technologies, significantly contribute to North America's market dominance.

Recent Developments

• In August 2025, Insmed Incorporated received approval from the U.S. Food and Drug Administration (FDA) for BRINSUPRI (brensocatib) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adults and adolescents aged 12 years and older. This oral, once-daily medication represents the first and only FDA-approved therapy specifically for NCFB, marking a significant advancement for patients with this chronic lung condition. BRINSUPRI, available in 10 mg and 25 mg doses, targets neutrophilic inflammation, which is a key driver of exacerbations and chronic airway damage in NCFB. The approval was supported by positive data from both the Phase 3 ASPEN and Phase 2 WILLOW clinical studies.

• In July 2024, Armata Pharmaceuticals announced the completion of patient enrollment for its Phase 2 Tailwind clinical trial. This study is assessing the efficacy of inhaled AP-PA02 in individuals diagnosed with non-cystic fibrosis bronchiectasis (NCFB) who also experience chronic *Pseudomonas aeruginosa* infection. The progression of this trial signifies an important step in developing bacteriophage therapies, which are designed to specifically target and eliminate bacterial infections. This research aims to address a critical unmet medical need for NCFB patients prone to recurrent and difficult-to-treat lung infections, representing a distinct approach in managing this progressive lung disease.

• In May 2024, Insmed Incorporated announced positive topline results from its global Phase 3 ASPEN study, evaluating brensocatib for non-cystic fibrosis bronchiectasis (NCFB). The trial demonstrated that both the 10 mg and 25 mg doses of brensocatib significantly reduced the rate of pulmonary exacerbations over 52 weeks compared to placebo. Additionally, the study achieved statistical significance for secondary endpoints, including the time to first pulmonary exacerbation and the proportion of patients remaining exacerbation-free. These promising results were crucial for the subsequent regulatory submission, positioning brensocatib as a potential first-in-class treatment targeting chronic airway inflammation in NCFB patients.

• In April 2024, 30 Technology received approval from the European Medicines Agency (EMA) to proceed with its Phase I/IIa NOPA study. This trial is designed to evaluate the safety, tolerability, and effectiveness of nebulized Nitric Oxide Formulations in patients with non-cystic fibrosis bronchiectasis (NCFB), particularly those infected with *Pseudomonas aeruginosa* or other potentially pathogenic microorganisms. This regulatory milestone permits the initiation of human trials for a novel therapeutic approach aimed at addressing bacterial infections and inflammation within the airways of NCFB patients, indicating ongoing research efforts to expand treatment options for this challenging condition.

Key Market Players

• Novartis AG
• Pfizer Inc.
• Bayer AG
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• GSK plc
• F. Hoffmann-La Roche Ltd.
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Ltd.
• Dr. Reddy’s Laboratories Ltd.

Report Scope:

In this report, the Global Non-Cystic Fibrosis Bronchiectasis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Non-Cystic Fibrosis Bronchiectasis Market, By Treatment:

o   Surgery

o   Physiotherapy

o   Vaccination

o   Airway pharmacotherapy

o   Antibiotics

o   Others

• Non-Cystic Fibrosis Bronchiectasis Market, By Diagnosis:

o   CT scan

o   Bronchoscopy

o   Chest X-ray

o   Lung function

o   Sputum culture test

o   Blood tests

o   Others

• Non-Cystic Fibrosis Bronchiectasis Market, By End use:

o   Hospitals & Clinics

o   Ambulatory Care Centers

o   Others

• Non-Cystic Fibrosis Bronchiectasis Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Non-Cystic Fibrosis Bronchiectasis Market.

Available Customizations:

Global Non-Cystic Fibrosis Bronchiectasis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Non-Cystic Fibrosis Bronchiectasis Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]